Skip to content
10-Q

Quarterly Report

KAIROS PHARMA, LTD. KAPA

0001493152-26-022796

← back to feed
Filed
May 13, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 11, 2026 21.41M sh
Shares Diluted Q1 2026 · Mar 31, 2026 21.01M sh
Shares Diluted Q1 2026 · Mar 31, 2025 15.88M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$1.04M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$714K
Cash And Equivalents Q1 2026 · Mar 31, 2026 $3.68M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $4.49M
Stockholders Equity Q1 2026 · Mar 31, 2026 $5.31M
Stockholders Equity Q1 2026 · Dec 31, 2025 $6.34M
Stockholders Equity Q1 2026 · Mar 31, 2025 $7.13M
Stockholders Equity Q1 2026 · Dec 31, 2024 $4.78M
Current Liabilities Q1 2026 · Mar 31, 2026 $431K
Current Liabilities Q1 2026 · Dec 31, 2025 $199K
Current Assets Q1 2026 · Mar 31, 2026 $4.44M
Current Assets Q1 2026 · Dec 31, 2025 $5.39M
Total Assets Q1 2026 · Mar 31, 2026 $5.74M
Total Assets Q1 2026 · Dec 31, 2025 $6.54M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.08
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.08
Eps Basic Q1 2026 · Mar 31, 2026 −$0.08
Eps Basic Q1 2026 · Mar 31, 2025 −$0.08
Sga Expense Q1 2026 · Mar 31, 2026 $1.01M
Sga Expense Q1 2026 · Mar 31, 2025 $773K
Rd Expense Q1 2026 · Mar 31, 2026 $684K
Rd Expense Q1 2026 · Mar 31, 2025 $493K
Net Income Q1 2026 · Mar 31, 2026 −$1.65M
Net Income Q1 2026 · Mar 31, 2025 −$1.26M
Operating Income Q1 2026 · Mar 31, 2026 −$1.69M
Operating Income Q1 2026 · Mar 31, 2025 −$1.27M